Skip to main content
SpringerLink
Log in

Borderline Resectable and Locally Advanced Pancreatic Cancer

  • Chapter
  • First Online:
Pancreatic Cancer

  • 164 Accesses

Abstract

While for anatomically and borderline resectable (AR and BR) pancreatic adenocarcinoma (PDAC) surgery remains the mainstay of the multimodality treatment plan, the treatment of locally advanced (LA) PDAC remains more nuanced because not every patient is truly on a surgical pathway. LA PDAC encompasses a spectrum of presentations ranging from tumors which can be potentially downstaged to BR or AR following systemic chemotherapy to those which truly remain unresectable due to sustained arterial encasement or unreconstructible venous involvement. At MD Anderson Cancer Center, clinical staging for BR PDAC is built around our “A-B-C” system, which classifies clinical presentations by tumor anatomy (“A”), tumor biology (“B”), and patient condition and comorbidities (“C”). Induction (often colloquially called “neoadjuvant”) therapy putatively treats the micro-metastatic disease that is almost universal in PDAC cases and allows time for medical optimization of the patient while tumor biology declares itself. For patients who undergo resection, the quality-of-life and cancer-related goals include return to intended oncologic therapy, low/no-complication surgery, and margin-negative resection. For all patients presenting with BR and LA PDAC, multidisciplinary management is required.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

    Article  PubMed  Google Scholar 

  2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.

    Article  CAS  PubMed  Google Scholar 

  3. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.

    Article  CAS  PubMed  Google Scholar 

  4. Cloyd JM, Katz MH, Prakash L, et al. Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience. J Gastrointest Surg. 2017;21(1):164–74.

    Article  PubMed  Google Scholar 

  5. Katz MH, Ahmad S, Nelson H. Borderline resectable pancreatic cancer: pushing the technical limits of surgery. Bull Am Coll Surg. 2013;98(1):61–3.

    PubMed  Google Scholar 

  6. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46; discussion 846-838.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tzeng CW, Fleming JB, Lee JE, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19(6):2045–53.

    Article  PubMed  Google Scholar 

  8. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11.

    Article  PubMed  Google Scholar 

  9. Hayasaki A, Isaji S, Kishiwada M, et al. Survival analysis in patients with pancreatic ductal adenocarcinoma undergoing chemoradiotherapy followed by surgery according to the international consensus on the 2017 definition of borderline resectable cancer. Cancer. 2018;10(3):65.

    Article  Google Scholar 

  10. Tzeng CW, Katz MH, Fleming JB, et al. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014;18(1):146–55; discussion 155–146.

    Article  PubMed  Google Scholar 

  11. Newhook TE, Vreeland TJ, Griffin JF, et al. Prognosis associated with CA19-9 response dynamics and normalization during neoadjuvant therapy in resected pancreatic adenocarcinoma. Ann Surg. 2023;277(3):484–90.

    Article  PubMed  Google Scholar 

  12. Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB. 2014;16(5):430–8.

    Article  PubMed  Google Scholar 

  13. Satoi S, Murakami Y, Motoi F, et al. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. J Gastrointest Surg. 2015;19(1):6–14; discussion 14.

    Article  PubMed  Google Scholar 

  14. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. van Veldhuisen E, van den Oord C, Brada LJ, et al. Locally advanced pancreatic cancer: work-up, staging, and local intervention strategies. Cancer. 2019;11(7):976.

    Article  Google Scholar 

  16. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56.

    Article  PubMed  Google Scholar 

  17. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del CC. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135(4):409–14; discussion 414-405.

    Article  CAS  PubMed  Google Scholar 

  18. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013;31(1):23–9.

    Article  CAS  PubMed  Google Scholar 

  19. Perri G, Prakash L, Katz MHG. Defining and treating borderline resectable pancreatic cancer. Curr Treat Options in Oncol. 2020;21(9):71.

    Article  Google Scholar 

  20. Denbo JW, Bruno ML, Cloyd JM, et al. Preoperative chemoradiation for pancreatic adenocarcinoma does not increase 90-day postoperative morbidity or mortality. J Gastrointest Surg. 2016;20(12):1975–85.

    Article  PubMed  Google Scholar 

  21. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  22. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  Google Scholar 

  23. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(4):439–57.

    Article  CAS  Google Scholar 

  24. Perri G, Prakash LR, Katz MHG. Response to preoperative therapy in localized pancreatic cancer. Front Oncol. 2020;10:516.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.

    Article  PubMed  Google Scholar 

  26. Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22(4):1153–9.

    Article  PubMed  Google Scholar 

  27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  PubMed  Google Scholar 

  28. Eshmuminov D, Aminjonov B, Palm RF, et al. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Ann Surg Oncol. 2023;30(7):4417–28.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in pancreas cancer: spectrum, current management, challenges and future prospects. Cancer Manag Res. 2020;12:2731–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Prakash LR, Katz MHG. Multimodality management of borderline resectable pancreatic adenocarcinoma. Chin Clin Oncol. 2017;6(3):27.

    Article  PubMed  Google Scholar 

  31. Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22.

    Article  PubMed  Google Scholar 

  32. Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Cloyd JM, Crane CH, Koay EJ, et al. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016;122(17):2671–9.

    Article  CAS  PubMed  Google Scholar 

  34. Katz MH, Wang H, Balachandran A, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012;16(1):68–78; discussion 78-69.

    Article  PubMed  Google Scholar 

  35. Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol. 2011;18(3):619–27.

    Article  PubMed  Google Scholar 

  36. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14(4):317–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015;220(4):530–6.

    Article  PubMed  Google Scholar 

  38. Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol. 2012;19(1):169–75.

    Article  PubMed  Google Scholar 

  39. Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–91.

    Article  PubMed  Google Scholar 

  40. van Hilst J, de Rooij T, Bosscha K, et al. Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. Lancet Gastroenterol Hepatol. 2019;4(3):199–207.

    Article  PubMed  Google Scholar 

  41. Nassour I, Winters SB, Hoehn R, et al. Long-term oncologic outcomes of robotic and open pancreatectomy in a national cohort of pancreatic adenocarcinoma. J Surg Oncol. 2020;122(2):234–42.

    Article  PubMed  Google Scholar 

  42. Bilimoria KY, Bentrem DJ, Lillemoe KD, Talamonti MS, Ko CY. Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst. 2009;101(12):848–59.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110(6):1227–34.

    Article  PubMed  Google Scholar 

  44. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246(2):173–80.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Katz MH, Lee JE, Pisters PW, Skoracki R, Tamm E, Fleming JB. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg. 2012;215(2):e11–8.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Kim BJ, Prakash L, Narula N, et al. Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. HPB. 2019;21(6):662–8.

    Article  PubMed  Google Scholar 

  47. Parker NH, Basen-Engquist K, Rubin ML, et al. Factors influencing exercise following pancreatic tumor resection. Ann Surg Oncol. 2020;28:2299–309.

    Article  PubMed  Google Scholar 

  48. Parker NH, Lee RE, O’Connor DP, et al. Supports and barriers to home-based physical activity during preoperative treatment of pancreatic cancer: a mixed-methods study. J Phys Act Health. 2019;16(12):1113–22.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Cloyd JM, Nogueras-Gonzalez GM, Prakash LR, et al. Anthropometric changes in patients with pancreatic cancer undergoing preoperative therapy and pancreatoduodenectomy. J Gastrointest Surg. 2018;22(4):703–12.

    Article  PubMed  Google Scholar 

  50. Ngo-Huang A, Holmes HM, des Bordes JKA, et al. Association between frailty syndrome and survival in patients with pancreatic adenocarcinoma. Cancer Med. 2019;8(6):2867–76.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Klaiber U, Probst P, Strobel O, et al. Meta-analysis of delayed gastric emptying after pylorus-preserving versus pylorus-resecting pancreatoduodenectomy. Br J Surg. 2018;105(4):339–49.

    Article  CAS  PubMed  Google Scholar 

  52. Liu L, Katz MH, Lee SM, et al. Superior mesenteric artery margin of posttherapy pancreaticoduodenectomy and prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2015;39(10):1395–403.

    Article  PubMed  Google Scholar 

  53. Kooby DA, Lad NL, Squires MH 3rd, et al. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Ann Surg. 2014;260(3):494–501; discussion 501-493.

    Article  PubMed  Google Scholar 

  54. Jung JP, Zenati MS, Dhir M, et al. Use of video review to investigate technical factors that may be associated with delayed gastric emptying after pancreaticoduodenectomy. JAMA Surg. 2018;153(10):918–27.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Newhook TE, Vega EA, Vreeland TJ, et al. Early postoperative drain fluid amylase in risk-stratified patients promotes tailored post-pancreatectomy drain management and potential for accelerated discharge. Surgery. 2020;167(2):442–7.

    Article  PubMed  Google Scholar 

  56. Beane JD, House MG, Ceppa EP, Dolejs SC, Pitt HA. Variation in drain management after pancreatoduodenectomy: early versus delayed removal. Ann Surg. 2019;269(4):718–24.

    Article  PubMed  Google Scholar 

  57. Fagenson AM, Gleeson EM, Lau KKN, Karachristos A, Pitt HA. Early drain removal after hepatectomy: an underutilized management strategy. HPB. 2020;22(10):1463–70.

    Article  PubMed  Google Scholar 

  58. Ecker BL, McMillan MT, Allegrini V, et al. Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy: analysis of 2026 resections from the International, Multi-institutional Distal Pancreatectomy Study Group. Ann Surg. 2019;269(1):143–9.

    Article  PubMed  Google Scholar 

  59. Vreeland TJ, Katz MHG. Pancreatoduodenectomy: superior mesenteric artery dissection. American College of Surgeons. 2020. https://www.facs.org/quality-programs/cancer/acs-crp/oscs/video. Accessed 14 September 2020.

  60. Perri G, Prakash L, Qiao W, et al. Postoperative chemotherapy benefits patients who received preoperative therapy and pancreatectomy for pancreatic adenocarcinoma. Ann Surg. 2020;271(6):996–1002.

    Article  PubMed  Google Scholar 

  61. Schwarz L, Bruno M, Parker NH, et al. Active surveillance for adverse events within 90 days: the standard for reporting surgical outcomes after pancreatectomy. Ann Surg Oncol. 2015;22(11):3522–9.

    Article  PubMed  Google Scholar 

  62. Denbo JW, Bruno M, Dewhurst W, et al. Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy. Surgery. 2018;164(3):424–31.

    Article  PubMed  Google Scholar 

  63. Ayabe RI, Prakash LR, Bruno ML, et al. Differential gains in surgical outcomes for high-risk vs low-risk pancreatoduodenectomy with successive refinements of risk-stratified care pathways. J Am Coll Surg. 2023;237(1):4–12.

    Article  PubMed  Google Scholar 

  64. Newton AD, Newhook TE, Bruno ML, et al. Iterative changes in risk-stratified pancreatectomy clinical pathways and accelerated discharge after pancreaticoduodenectomy. J Gastrointest Surg. 2022;26(5):1054–62.

    Article  PubMed  Google Scholar 

  65. Arango NP, Prakash LR, Chiang YJ, et al. Risk-stratified pancreatectomy clinical pathway implementation and delayed gastric emptying. J Gastrointest Surg. 2021;25(9):2221–30.

    Article  PubMed  Google Scholar 

  66. Witt RG, Hirata Y, Prakash LR, et al. Comparative analysis of opioid use between robotic and open pancreatoduodenectomy. J Hepatobiliary Pancreat Sci. 2023;30(4):523–31.

    Article  PubMed  Google Scholar 

  67. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13.

    Article  PubMed  Google Scholar 

  68. Allen PJ, Gonen M, Brennan MF, et al. Pasireotide for postoperative pancreatic fistula. N Engl J Med. 2014;370(21):2014–22.

    Article  PubMed  Google Scholar 

  69. Liu X, Pausch T, Probst P, et al. Efficacy of pasireotide for prevention of postoperative pancreatic fistula in pancreatic surgery: a systematic review and meta-analysis. J Gastrointest Surg. 2020;24(6):1421–9.

    Article  PubMed  Google Scholar 

  70. Denbo JW, Slack RS, Bruno M, et al. Selective perioperative administration of pasireotide is more cost-effective than routine administration for pancreatic fistula prophylaxis. J Gastrointest Surg. 2017;21(4):636–46.

    Article  PubMed  Google Scholar 

  71. Sutton JM, Kooby DA, Wilson GC, et al. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg. 2014;18(9):1575–87.

    Article  PubMed  Google Scholar 

  72. Tzeng CW, Tran Cao HS, Lee JE, et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014;18(1):16–24; discussion 24-15.

    Article  PubMed  Google Scholar 

  73. Wu W, He J, Cameron JL, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21(9):2873–81.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2013;275(5):979–84.

    Google Scholar 

  75. Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156(3):591–600.

    Article  PubMed  Google Scholar 

  76. Birkmeyer JD, Finlayson SR, Tosteson AN, Sharp SM, Warshaw AL, Fisher ES. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery. 1999;125(3):250–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Ching-Wei D. Tzeng & Laura Prakash

Authors
  1. Ching-Wei D. Tzeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ching-Wei D. Tzeng .

Editor information

Editors and Affiliations

  1. GI Medical Oncology, The University of Texas MD Anderson Canc, Houston, TX, USA

    Shubham Pant

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tzeng, CW.D., Prakash, L. (2023). Borderline Resectable and Locally Advanced Pancreatic Cancer. In: Pant, S. (eds) Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-031-38623-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-38623-7_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-38622-0

  • Online ISBN: 978-3-031-38623-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation